IMW 2019 | Waldenström’s Macroglobulinemia venetoclax therapy

Jorge Castillo

Jorge Castillo, MD Dana-Farber Cancer Institute, Boston, MA, provides an update on phase II trials of venetoclax therapy as a treatment for Waldenström’s Macroglobulinemia patients, alongside an overview of the disease biology. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video